GLP-1 Weight Loss Drugs Face Legal and Safety Concerns as Medicare Coverage Expands to Seniors

GLP-1 weight loss medications like Saxenda face mounting legal challenges as patients report developing non-arteritic anterior ischemic optic neuropathy (NAION), a condition causing permanent vision loss. In December 2025, federal courts established MDL No. 3163 under Judge Karen S. Marston to coordinate these claims. Research indicates patients on GLP-1 drugs face a significantly higher risk of NAION, prompting lawsuits alleging Novo Nordisk failed to provide adequate warnings.

Saxenda NAION vision loss lawsuits

• ▪At least 110 Saxenda non-arteritic anterior ischemic optic neuropathy (NAION) claims have been filed by families.
• ▪Saxenda vision loss lawsuits allege that Novo Nordisk failed to adequately warn doctors and patients of the potential link between liraglutide and non-arteritic anterior ischemic optic neuropathy (NAION) on the drug's label.
• ▪Lawsuits claim Novo Nordisk continued to market Saxenda for weight loss without disclosing researchers' findings regarding non-arteritic anterior ischemic optic neuropathy (NAION) risks.

GLP-1 drug NAION risk research

• ▪The 2024 JAMA Ophthalmology study analyzed health records from 16,827 patients and found the highest risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) occurred within the first year of starting semaglutide treatment.
• ▪According to Epic Research, patients with type 2 diabetes prescribed liraglutide have a 179% higher likelihood of developing non-arteritic anterior ischemic optic neuropathy (NAION) than those prescribed other diabetes medications.
• ▪A 2024 study in JAMA Ophthalmology found that patients prescribed semaglutide faced a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) than patients on other weight-loss medications.

NAION symptoms medical impact

• ▪Non-arteritic anterior ischemic optic neuropathy (NAION) symptoms include sudden, painless vision loss or a dark, blurry patch in one eye, often noticed immediately upon waking.
• ▪Non-arteritic anterior ischemic optic neuropathy (NAION) is caused by a sudden reduction or cutoff of blood flow to the front portion of the optic nerve, starving nerve cells of oxygen.
• ▪There is currently no Food and Drug Administration (FDA) approved treatment that can reliably reverse vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION).

Federal MDL 3163 litigation status

• ▪The Honorable Karen S. Marston oversees MDL No. 3163, which names Novo Nordisk and Eli Lilly and Company as defendants.
• ▪In December 2025, the U.S. Judicial Panel on Multidistrict Litigation established MDL No. 3163 in the U.S. District Court for the Eastern District of Pennsylvania to handle GLP-1 drug NAION claims.
• ▪At the time MDL No. 3163 was created, 30 federal lawsuits and more than 40 state court cases had been filed regarding GLP-1 drug-related vision loss.

Lawsuit eligibility requirements

• ▪Lawsuit eligibility requires that the patient had no prior history of non-arteritic anterior ischemic optic neuropathy (NAION) before starting the GLP-1 medication.
• ▪Eligibility for a GLP-1 NAION lawsuit generally requires a documented medical diagnosis of non-arteritic anterior ischemic optic neuropathy (NAION) or a related optic nerve injury from an eye doctor.
• ▪Individuals may be eligible to file a GLP-1 NAION lawsuit if they used Saxenda or another GLP-1 drug for weight management and experienced sudden, painless vision loss.

Legal process compensation claims

• ▪Sokolove Law represents clients in GLP-1 NAION lawsuits on a contingency-fee basis, requiring no upfront costs from the plaintiffs.
• ▪Plaintiffs in Saxenda lawsuits seek compensation for medical bills, lost income, ongoing care needs, and damages for pain and suffering caused by permanent vision loss.

2 sources